Supramolecular glycodendrimer-based hybrid drugs

Paolino M, Komber H, Mennuni L, Caselli G, Appelhans D, Voit B, Cappelli A (2014)

Publication Type: Journal article

Publication year: 2014

Journal

Biomacromolecules American Chemical Society

Book Volume: 15

Pages Range: 3985-3993

Journal Issue: 11

DOI: 10.1021/bm501057d

Abstract

Specific noncovalent interactions are commonly used by nature to modulate numerous processes including cell recognition, viral adhesion, and transmembrane communications. Here we report on the design, synthesis, and preliminary characterization of new supramolecular glycodendrimer-based hybrid drugs based on adamantyl-modified glycodendrimers of third, fourth, or fifth generation (mPPI-G3-AdaB, mPPI-G4-AdaB, and mPPI-G5-AdaB) and a new heterobifunctional ligand. This component was tailored to bind through noncovalent interactions both the multimeric natural 5-HT3 receptor (through an optimized arylpiperazine pharmacophore) and the adamantyl groups located on the glycodendrimer surfaces (through a β-cyclodextrin residue) giving rise to biorelevant supramolecular constructs.

Involved external institutions

Università degli Studi di Siena (UNISI) / University of Siena

Italy (IT) Leibniz-Institut für Polymerforschung Dresden e. V.

Germany (DE) Rottapharm Biotech S.r.l.

Italy (IT)

How to cite

APA:

Paolino, M., Komber, H., Mennuni, L., Caselli, G., Appelhans, D., Voit, B., & Cappelli, A. (2014). Supramolecular glycodendrimer-based hybrid drugs. Biomacromolecules, 15(11), 3985-3993. https://doi.org/10.1021/bm501057d

MLA:

Paolino, Marco, et al. "Supramolecular glycodendrimer-based hybrid drugs." Biomacromolecules 15.11 (2014): 3985-3993.

BibTeX: Download